A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
Baylor College of Medicine
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Washington University School of Medicine
Ohio State University Comprehensive Cancer Center
Ruijin Hospital
City of Hope Medical Center
Wake Forest University Health Sciences
Stanford University
University of Nebraska
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Children's Hospital Medical Center, Cincinnati
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
University of Wisconsin, Madison
University of Wisconsin, Madison
Mayo Clinic
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Swiss Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Virginia Commonwealth University
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of California, San Francisco
Massachusetts General Hospital
Alliance for Clinical Trials in Oncology
Rutgers, The State University of New Jersey
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
Fred Hutchinson Cancer Center
Ohio State University Comprehensive Cancer Center
Rutgers, The State University of New Jersey
Boston Medical Center
Fox Chase Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center